Strattera

This page shows the latest Strattera news and features for those working in and with pharma, biotech and healthcare.

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Strattera (atomoxetine) and erectile dysfunction therapy Cialis (tadalafil).

Shire launches long-acting ADHD drug Intuniv in UK

It is also the first alternative to Eli Lilly's non-stimulant ADHD therapy Strattera (atomoxetine) in Europe, providing another option for the approximately 10% of people with the condition who
Lilly feels effects of Cymbalta competition

to $588m and attention-deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine) brought in $201m, up 23 per cent.
Scotland first in UK to back Pfizer's Inlyta

month - along with Roche's Lucentis (ranibizumab) for pathologic myopia and Eli Lilly's attention deficit hyperactivity disorder (ADHD) therapy Strattera (atomoxetine).
Lilly’s Strattera wins new adult ADHD licence in UK

Adults in the UK with attention deficit hyperactivity disorder (ADHD) who were not prescribed medicine as a child will now have access to Lilly's Strattera after it was approved by ... Strattera's new licence is backed by results from clinical trials
Lilly's Strattera patent upheld in US

The US court of appeals has upheld the validity of Eli Lilly &Company's patent for ADHD drug Strattera. ... However, the most recent decision upholds Lilly's method-of-use patent which provides protection for Strattera until May, 2017.

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Challenging perceptions

These classes were methylphenidate-based products like Johnson &Johnson's Concerta (methylphenidate hydrochloride) and Lilly's non-stimulant Strattera (atomoxetine).